Clinical trial · Interventional
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): low enrollment
Summary
Brief summary (as posted)
In standard prostate brachytherapy treatment, the seeds are placed throughout the prostate to treat the entire gland. This is done because, in the past, it was impossible to know where the cancer was located within the prostate. Multiparametric magnetic resonance imaging (MRI) can identify tumor(s) with a high degree of accuracy. This trial will assess whether using MRI to guide prostate brachytherapy can result in less chronic toxicity by allowing lower doses to be delivered to the regions of the prostate without tumor while simultaneously allowing higher doses to the tumor. Subjects enrolled in this study will then be followed over two years and evaluated for toxicity. In addition, after two years they will undergo an MRI and a biopsy to assess the cancer control rate of the treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| An MRI-based technique to identify prostate cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pre-implant MRI images and planning
- interventionNames
- Other: An MRI-based technique to identify prostate cancer
Primary outcomes (1)
- measure
- Chronic toxicity as assessed by the Common Toxicity Criteria Version 4.0
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical stage ≤ T2b according to the American Joint Commission on Cancer 6th Edition28 * PSA ≤ 15 ng/ml * Gleason sum on biopsy ≤ 6 or 3+4=7 * Prostate volume ≤ 60 cc * Willing to continue follow-up for at least two years Exclusion Criteria: * Prior hormone therapy * Prior radiotherapy * History of collagen vascular disease * History of inflammatory bowel disease
References
Publications (0)
Data not yet available